Sign In

Does Screening Baby Boomers for Hepatitis C Work?

November 11, 2014

A study presented at the annual meeting of the American Association for the Study of Liver Diseases reported that the current age-based screening recommendation from the Centers for Disease Control and Prevention (CDC) is five times more effective in identifying people currently or previously infected with hepatitis C virus when compared to the previous screening strategy.

What Is the Real Cost of Treating All Patients with Hepatitis C?

November 10, 2014

Researchers from MD Anderson reported at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) their attempt to estimate the cost of treating all patients in the United States with hepatitis C virus (HCV) and compare it to the potential cost savings.

Treating All Patients with Hepatitis C Who Would Be Diagnosed by Age-based Screening Is Cost Effective

November 10, 2014

The newest and most effective drugs for the treatment of hepatitis C have a cure rate of up to 98 percent, but the cost of these therapies has been controversial. Accurately assessing the cost of treating all patients with HCV in the US has yet to be determined.

Finding Hepatitis C in High-Risk Populations: How New York City Did It

November 10, 2014

It is estimated that 2.4 percent of New York City (NYC) residents have HCV infection, but half do not know their status. To address this gap, the NYC Department of Health and Mental Hygiene launched the Check Hep C Program, which, in its first year, helped increase the rate of complete hepatitis C (HCV) diagnostic testing among at risk populations and has successfully linked more people to HCV supportive services, care, and treatment.

Transplanting Patients with HIV and Liver Cancer

November 10, 2014

Liver transplantation is a therapeutic option for selected patients with liver cancer with high 5-year survival rates of 75 – 80 percent. HIV-infected patients often do not have access to liver transplantation, and experience with HIV-infected patients with liver cancer undergoing liver transplantation is limited.

Are US Veterans Being Appropriately Tested and Treated for Hepatitis B?

November 9, 2014

Attendees of the annual meeting of the American Association for the Study of Liver Diseases (AASLD) listened to the results of a study on the adherence to its practice guidelines on testing for hepatitis B virus (HBV). Drs. Marina Serper, Kimberly Forde, and David E. Kaplan, of the University of Pennsylvania and Philadelphia VA Medical Center, examined the VA’s Corporate Data Warehouse and concluded that the rates of serologic testing for HBV conducted by the VA weresuboptimal as recommended by the AASLD practice guideline.

What Does Social Media and Crowdsourcing Have to Do With Women and Liver Disease?

November 9, 2014

Autoimmune hepatitis is a chronic liver disease that is found more frequently in women than men. Researchers at Indiana University studied the environmental exposures possibly related to autoimmune hepatitis and reported their findings at the annual meeting of the American Association for the Study of Liver Diseases. "Interestingly, autoimmune hepatitis is quite far behind other autoimmune liver diseases in terms of environmental risk assessment," said Craig Lammert, MD, principal investigator on the study.

What’s New at The Liver Meeting® 2014

October 31, 2014

Preparing for our upcoming annual meeting in Boston has AASLD staff, leadership, and committees working frantically to get ready.

PCORI Discovers Hepatitis C

October 30, 2014

On October 17 In Washington, DC, the Patient-Centered Outcomes Research Institute (PCORI) has invited AASLD to participate in a meeting to discuss the clinical issues related to choosing treatments for hepatitis C infection.

The White House Recognizes AASLD for Hepatitis C Guidance Work

October 28, 2014

The recent World Hepatitis Day event at the White House presented a terrific opportunity for the nation to focus on the “silent epidemic” of viral hepatitis. The event on July 30 brought together researchers, clinicians, patient advocates, corporate officers, and many other stakeholders in a two and a half hour session that was webcast live from the Old Executive Office Building in the White House complex in Washington, DC.

Pages